ANI Aims For CGT Top Spot With Two New Launches
Firm Says Latest Competitive Generic Therapy Approvals Make It Joint Leader In US
ANI Pharmaceuticals has heralded the approval and launch of two new US competitive generic therapies as giving it a joint leadership position in the CGT space.
You may also be interested in...
Management at ANI has upped its estimates for the second time this year after another impressive quarter, driven by Cortrophin gel and a strong generics performance.
Padagis has launched budesonide 2mg rectal foam, the first US generic version of Uceris, with 180 days of competitive generic therapy exclusivity.
With Amneal delivering what it described as a “solid” set of financials for 2022, the company has reaffirmed that it sees more value in moving increasingly into complex generics and bolstering its nascent biosimilars business.